Compare the target, disease, product status, and exact population—not headline response rates.
Rows are educational evidence controls. They do not establish eligibility, hospital supply, manufacturing success, price, insurance coverage, or individual benefit.
HB / CAR-T / DATA
Approved products and research pathways are separated
A regulator-approved product is approved only for its exact labelled population. A registered or published study is not marketed care, and products cannot be compared across unrelated trials by response rate.
PLAIN LANGUAGE
Medical terms in plain language
Hover, focus, or tap an underlined term for a short definition. These definitions do not replace the treating team’s explanation.
Disease-to-evidence search
Describe a disease or treatment question in ordinary words.
This local search finds relevant evidence pages. It does not diagnose, recommend a therapy, assess eligibility, or send your text to an external model.
Verified China indications include later-line large B-cell lymphoma, defined follicular lymphoma, and later-line mantle-cell lymphoma after a BTK inhibitor.
A proposed second-line LBCL filing was accepted for review, not verified as approved on this source.
Conditionally approved for adults with relapsed or refractory multiple myeloma after progression following three or more prior lines including a proteasome inhibitor and immunomodulatory agent.
Conditional approval, exact prior therapy and current centre supply must be checked.
Adults with relapsed or refractory multiple myeloma after progression following at least three prior lines including a proteasome inhibitor and immunomodulatory agent.
Pivotal-study institutions do not automatically prove current commercial access.
Conditionally approved for adults with relapsed or refractory multiple myeloma after three or more prior lines and progression, including a proteasome inhibitor and immunomodulatory agent.
China label and access must not be replaced with a U.S. or EU indication.
Individual clinical courses—reported, not promised.
These neutral summaries come from peer-reviewed case reports or provider-owned public reports. They are not testimonials, representative outcomes, comparative evidence, or a treatment recommendation.
Hospital-owned reportReport: 2 Jun 2026 · episode: 2023
International adult with PMBCL treated in Shanghai
Case context
Primary mediastinal large B-cell lymphoma after prior multimodal treatment
Treatment reported
Axicabtagene ciloleucel CAR-T
Setting
Jiahui International Hospital, Shanghai
Observed course
The hospital reported improved tumour-related pain and clinically stable discharge three weeks after infusion.
Safety or complication
Fever, hypotension and vomiting were described as CRS symptoms; the report did not state a CRS grade.
Reported follow-up
Three weeks to discharge; later outcome not reported
Why this cannot be generalisedHospital-authored single case with short follow-up; no long-term response or survival conclusion.
International adult receiving satri-cel in Shanghai
Case context
Advanced gastroduodenal adenocarcinoma with CLDN18.2-positive, HER2-negative testing
Treatment reported
Satri-cel (CT041) CAR-T
Setting
Jiahui International Cancer Center, Shanghai
Observed course
The provider reported resolution of malignant ascites by day 10, drain removal, and discharge after more than one month in Shanghai.
Safety or complication
No treatment-related adverse event was specified in the provider summary.
Reported follow-up
To discharge on 16 Aug 2026; longer follow-up not reported
Why this cannot be generalisedShort provider-authored single case; it does not establish radiographic response, durability or benefit for another patient.
BCMA CAR-T case in secondary plasma-cell leukaemia
Case context
Secondary plasma-cell leukaemia after heavily pretreated multiple myeloma
Treatment reported
Investigational anti-BCMA CAR-T in a registered study
Setting
Beijing Boren Hospital
Observed course
The article reported stringent complete response for nine months; later venetoclax was used, with a further seven months in complete response before later relapse.
Safety or complication
Grade 1 CRS for about nine days, oral ulcer, cytopenia and suspected severe bacterial infection were reported.
Reported follow-up
Sixteen-month progression-free interval reported after CAR-T
Why this cannot be generalisedOne rare, highly selected study case; later therapy confounds durability and the construct is not a marketed-product claim.
HarbourBridge did not treat, recruit, interview, or verify these individuals independently and has no relationship implied by inclusion.
NEXT / 02
Find evidenced treatment centres
A regulator-approved product is approved only for its exact labelled population. A registered or published study is not marketed care, and products cannot be compared across unrelated trials by response rate.